CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Bevacizumab 1.25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01309451
NCT01309451Phase 4Completed
CompareCT.gov

A Single Masked, Randomized Controlled Study to Assess Efficacy of Ozurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Diabetic Macular Edema

Maturi, Raj K., M.D., P.C.·interventional·Posted Mar 7, 2011·Updated Oct 29, 2014

In Brief

A Phase 4 clinical trial evaluating Bevacizumab and dexamethasone intravitreal implant for Diabetic Macular Edema. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The investigators hypothesize that a combination treatment with Avastin and Ozurdex will result in a more rapid improvement of visual acuity compared to the use of Avastin alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 7, 2011
Enrollment StartMar 1, 2011
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 15.3 years ago

Interventions

Bevacizumabdrug

intravitreal, 1.25mg., monthly

dexamethasone intravitreal implantdrug

0.7mg, intravitreal every 4 months